Community Adoption / Mr Federer, page-47

Many of the patients who have now invested in PAR did so because they witnessed first hand the benefits that PPS provided them in treating a debilitating disease. Many of these patient investors are people that had been using compounding chemists for Pentosan before PAR even came onto the scene.

There won't be much in the way of Zilosul being a blockbuster drug if it is approved. Make no mistake about that. We only need to look at the figures that Humira produced for AbbVie in treating RA, which is a much smaller market than OA (but one that PPS treats too, see Linda Curreri's book)